| First character of title | Commenter | Comment Information |
.
|
Title: Executive Director
Organization: Alliance of Dedicated Cancer Centers
Date: 10/08/2012
Comment:
Members Include 11 Exempt Cancer Centers
On behalf of the Alliance of Dedicated Cancer Centers (ADCC) we want to extend our support for the proposed coverage of PET imaging for solid tumors for subsequent treatment strategy. We feel this
More opens in new window
|
A
|
Title: Sr. Policy Director
Organization: Medical Imaging & Technology Alliance
Date: 10/11/2012
Comment:
Dear Dr. Roche and Mr. Caplan:
The Medical Imaging & Technology Alliance (MITA) appreciates this opportunity to respond to the Centers for Medicare and Medicaid Services’ (CMS’) request for comments on the reconsideration request
More opens in new window
|
|
Title: Curtis Distinguished Professor
Organization: MD Anderson Cancer Center
Date: 10/11/2012
Comment:
PET-CT is easily the most valuable way to get information about locations of sarcoma metastases adn response to therapy. It should be considered "standard of care" for bone and soft tissue evaluation for presence or absence of osteosarcoma,
More opens in new window
|
B
|
Date: 09/16/2012
Comment:
I have found PET CT to be a very usefull tool in helping to decide the appropriate treatment approach for individual patients.
In some cases it has been the only tool that has demonstrated abnormalities that have lead to changes it treatment
More opens in new window
|
|
Organization: Moffitt Cancer Center
Date: 10/08/2012
Comment:
I beleive that it is important to compare the effectivness of PET with respect to other sstaging and response assessing technique. of solid tumors. I am not sure that NOPR will provide that information. I would prefer direct studies in specific
More opens in new window
|
|
Title: Pre-Authorization Coordinator
Organization: Weill Cornell Imaging @ NY Presbyterian
Date: 10/03/2012
Comment:
We hope that CMS will now expand its’coverage for FDG-PETS as well as NaF-PETS based on the data that has been acquired over the years. Our referring physicians continue to stress the importance of these PET scans when taking into consideration
More opens in new window
|
|
Title: Medical Director
Organization: PET Imaging Corporation
Date: 09/21/2012
Comment:
As a radiologist working with PET-CT for the last 6 years since its incorporation into our practice I have seen first hand the tremendous benefits this procedure has in the early identification and early assesment of response to therapy that PET
More opens in new window
|
|
Title: President
Organization: World Molecular Imaging Society
Date: 10/04/2012
Comment:
The World Molecular Imaging Society (WMIS), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the American College of Radiology (ACR) are pleased to provide this joint comment in support of the proposal of the National Oncologic
More opens in new window
|
|
Date: 10/12/2012
Comment:
Louis B. Jacques, MD
Director, Coverage and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Blvd
Baltimore, MD 21244
RE: Reconsideration of Section 220.6 of the NCD on Positron
More opens in new window
|
C
|
Title: Physician
Organization: Mercy Clinic Medical Oncology
Date: 10/08/2012
Comment:
PET scans are useful for evaluating abnormalities seen on other imaging modalities such as CT scans and MRI scans. They can often replace multiple other imaging tests such as a combination of bone scan and CT scans used in some malignancies.
More opens in new window
|
|
Date: 10/11/2012
Comment:
I believe that PET is a great modality to diagnose and stage the extent of cancer. By expanding the coverage the patient could avoid delays and multiple tests in a time to get the treatment they need done as soon as
More opens in new window
|
|
Date: 10/08/2012
Comment:
PET scan help us significantly to manage our lung, esophageal and other thoracic diseases. It stages pts more accurately and avoids unnecessary tests and
More opens in new window
|
|
Date: 10/10/2012
Comment:
As a radiation oncologist, PET is essential in targeting treatment, as well as following patients post treatment. Often times, rare tumors are treated. While they do take up FDG, there is extra paperwork in getting these scans approved which
More opens in new window
|
|
Title: Distinguished Professor & Executive Chair
Organization: Dept. of Ob/Gyn, UCLA
Date: 09/18/2012
Comment:
The PET scan has been very useful with regard to the diagnosis of women’s reproductive cancers. We have had numerous occasions when an MRI was negative but subsequently cancer lesions were found with a PET CT. It is therefore very important from
More opens in new window
|
|
Title: Chief of Nuclear Medicine
Organization: Yale University School of Medicine
Date: 09/26/2012
Comment:
FDG-PET scanning has been helpful in many more oncologic diagnoses than is currently covered by CMS. Many of our medical oncologists and surgeons have informed us that knowing the extent of disease has been invaluable in arriving at their final
More opens in new window
|
|
Title: Alando J. Ballantyne Distinguished Chair of Surger
Organization: The University of Texas MD Anderson Cancer Center
Date: 10/10/2012
Comment:
I have been practicing in surgical oncology for nearly 24 years. Thoughtful utilization of PET imaging has dramatically contributed to the evaluation and effective management of patients.
In particular, my surgical practice has focued upon
More opens in new window
|
D
|
Date: 09/17/2012
Comment:
I would like CMS know that I think it would be a big disservice to our patients the mid-Atlantic region if no reimbursement is made for PET and PET/CT scans that are currently covered for subsequent treatment strategy (STS) under NOPR. There are
More opens in new window
|
|
Date: 10/11/2012
Comment:
I am a medical oncologist who sees a lot of small cell lung. I have been using PET scanning for the past year to stage these patients. I have had a large number of patients whose CT scans indicated limited stage disease but on PET imaging found to
More opens in new window
|
|
Title: Oncology Medical Director
Organization: Baptist Health Corbin
Date: 09/18/2012
Comment:
PET is a standard of care for lymphoma, breast cancer, lung cancer and colon
More opens in new window
|
E
|
Title: Alex Grass Professor of Oncology
Organization: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Date: 10/12/2012
Comment:
October 12, 2012
Louis B. Jacques, MD
Director, Coverage and Analysis Group
Centers for Medicare & Medicaid Services
7500 Security Blvd
Baltimore, MD 21244
RE: Reconsideration of Section 220.6 of
More opens in new window
|
F
|
Title: Assistant Professor
Organization: U.T. MD Anderson Cancer Center
Date: 10/09/2012
Comment:
I am writing in support of the proposed further expansion of FDG-PET coverage as proposed by the National Oncologic PET Registry (NOPR) Working Group. I urge the Centers for Medicare and Medicaid Services (CMS) to reconsider the current National
More opens in new window
|
|
Title: Doctor
Organization: University of Virginia Cancer Center
Date: 10/04/2012
Comment:
FDG-PET is an established cancer imaging method which I use to care for my patients at the University of Virginia Cancer Center. While it is clear that FDG-PET does not perform uniformly in every type of cancer, neither do other imaging techniques
More opens in new window
|
|
Title: Medical Director of Nuclear Medicine and PET Imagi
Organization: Pitts Radiology
Date: 10/09/2012
Comment:
I introduced positron imaging to my state, and I have used it successfully for about 16 years, first with coincidence imaging, then with dedicated PET, and now with PET/CT. It is an incredibly powerful tool, and we need to do whatever is necessary
More opens in new window
|
G
|
Title: mgr pet/ct
Organization: University Hospital
Date: 09/19/2012
Comment:
From what I am reading, there is consideration of Medicare covering all tumor evaluation and there would not be a NOPR. I know that would help our facility to be for efficient in patient care of our medicare population. We want the best medical
More opens in new window
|
|
Title: physician
Organization: Cleveland Clinic
Date: 10/10/2012
Comment:
I have been using FDG PET-CT imaging to stage and treatment plan for radiaition since 2000, or over 12 years now. A FDG PET-CT is the most important tool I use during radiation planning to be able to define the tumor volume for IMRT planning,
More opens in new window
|
